B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been steadily improving, thanks to ongoing research aimed at discovering more effective treatment methods..

B细胞淋巴瘤是非霍奇金淋巴瘤的一种亚型，在美国是领先的癌症诊断，占所有病例的85%。该癌症靶向淋巴系统，包括负责体内液体运输的淋巴结，血管和相关组织。由于正在进行的旨在发现更有效治疗方法的研究，B细胞淋巴瘤患者的前景一直在稳步改善。。

LAS VEGAS, Nov. 22, 2023 /PRNewswire/ -- B-cell lymphoma is a diverse group of blood cancers that originate from abnormal B lymphocytes, a type of white blood cell crucial for the immune system. These lymphomas can manifest in various forms, including non-Hodgkin's lymphoma and Hodgkin's lymphoma, each with its unique characteristics.

拉斯维加斯，2023年11月22日/PRNewswire/-B细胞淋巴瘤是一组不同的血液癌症，起源于异常的B淋巴细胞，这是一种对免疫系统至关重要的白细胞。这些淋巴瘤可以以各种形式表现，包括非霍奇金淋巴瘤和霍奇金淋巴瘤，每种淋巴瘤都有其独特的特征。

B-cell lymphomas arise when B cells undergo mutations that lead to uncontrolled growth and the formation of tumors within lymph nodes and other lymphoid tissues. The symptoms and severity of B-cell lymphoma can vary widely, but they often include swollen lymph nodes, fatigue, night sweats, and unexplained weight loss.

当B细胞经历导致不受控制的生长以及在淋巴结和其他淋巴组织内形成肿瘤的突变时，会出现B细胞淋巴瘤。B细胞淋巴瘤的症状和严重程度差异很大，但通常包括淋巴结肿大，疲劳，盗汗和不明原因的体重减轻。

Effective treatments for B-cell lymphoma may encompass chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation, with a specific approach tailored to the subtype and stage of the disease. Early diagnosis and advances in medical research have improved the prognosis for many individuals with B-cell lymphoma, offering hope for better outcomes and quality of life..

B细胞淋巴瘤的有效治疗可能包括化疗，放疗，免疫治疗和干细胞移植，并根据疾病的亚型和阶段采取特定的方法。早期诊断和医学研究的进展改善了许多B细胞淋巴瘤患者的预后，为更好的预后和生活质量提供了希望。。

DelveInsight has recently released a series of epidemiology-based market reports focusing on B-cell lymphoma including Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032  segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

DelveInsight最近发布了一系列基于流行病学的市场报告，重点关注B细胞淋巴瘤，包括弥漫性大B细胞淋巴瘤，滤泡性淋巴瘤，慢性淋巴细胞白血病，套细胞淋巴瘤，边缘区淋巴瘤，瓦尔登斯特伦巨球蛋白血症和伯基特淋巴瘤。这些报告包括全面了解当前的治疗实践，历史和预测的患者库，新兴药物，个体治疗的市场份额，以及2019年至2032年的历史和预测市场规模，分为7MM[美国，欧盟-4（意大利），西班牙，法国和德国），英国和日本]）。。

Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these B-cell lymphoma markets individually.

此外，这些报告还对在临床开发的不同阶段与其新兴候选人合作的知名公司进行了详尽的分析。让我们深入探讨这些B细胞淋巴瘤市场的评估。

To delve into the B-cell Non-Hodgkin lymphoma market landscape in more detail, access the B-Cell Non-Hodgkin Lymphoma Market Report

要更详细地了解B细胞非霍奇金淋巴瘤市场格局，请访问B细胞非霍奇金淋巴瘤市场报告

Diffuse Large B-cell Lymphoma (DLBCL) Market

弥漫性大B细胞淋巴瘤（DLBCL）市场

Diffuse large B-cell lymphoma (DLBCL) stands as the most prevalent subtype of non-Hodgkin lymphoma (NHL), originating from the transformation of B-lymphocytes. This cancer type takes root in both germinal center and post-germinal center B-cells. As per DelveInsight estimates, total incident cases of DLBCL in the 7MM were assessed to be ~73K in 2021, and are expected to increase during the study period (2019–2032).

弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤（NHL）中最普遍的亚型，起源于B淋巴细胞的转化。这种癌症类型在生发中心和生发后中心B细胞中都有根。根据DelveInsight的估计，在2021年，7MM的DLBCL事件总数估计为〜73K，预计在研究期间（2019-2032年）会增加。

Among the 7MM, the US accounted for the highest incidence cases of DLBCL, followed by EU4 and the UK, and Japan..

在7MM中，美国占DLBCL发病率最高的病例，其次是EU4，英国和日本。。

DLBCL treatment typically starts soon after diagnosis with the goal of achieving a long-lasting remission or cure. The primary approach involves a combination of chemotherapy and a monoclonal antibody targeting CD20. The most commonly used chemotherapy regimen for DLBCL is R-CHOP, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered in 21-day cycles.

DLBCL治疗通常在诊断后不久开始，目标是实现长期缓解或治愈。主要方法涉及化学疗法和靶向CD20的单克隆抗体的组合。DLBCL最常用的化疗方案是R-CHOP，其中包括利妥昔单抗，环磷酰胺，多柔比星，长春新碱和泼尼松，以21天的周期给药。

In some cases, etoposide can be added to the R-CHOP regimen, forming a combination known as R-EPOCH. Radiation therapy may also be considered. Many DLBCL patients achieve remission following initial treatment, but for those whose disease becomes treatment-resistant (refractory) or reoccurs (relapses), alternative therapies may prove effective..

在一些情况下，依托泊苷可以加入到R-CHOP方案中，形成称为R-EPOCH的组合。也可以考虑放射治疗。许多DLBCL患者在初始治疗后达到缓解，但对于那些疾病变得耐药（难治性）或复发（复发）的患者，替代疗法可能证明是有效的。。

As per DelveInsight analysis, the DLBCL market size in the 7MM was USD 3.7 billion in 2021 and the highest market share was captured by the US. The rise in DLBCL market growth throughout the forecasted timeframe can be attributed to the growing pipeline of candidates dedicated to enhancing DLBCL recovery therapies.

根据DelveInsight分析，2021年DLBCL市场规模为700万美元，最高市场份额被美国占据。在整个预测时间范围内DLBCL市场增长的增长可归因于候选人的不断增长致力于加强DLBCL恢复疗法。

Over the past few years, the FDA has endorsed seven novel treatments within the relapsed/refractory DLBCL category, spanning a range of modalities such as CAR-T therapies, small molecules, monoclonal antibodies, and antibody-drug conjugates..

在过去几年中，FDA批准了复发/难治性DLBCL类别中的七种新型治疗方法，涵盖了一系列方式，如CAR-T疗法，小分子，单克隆抗体和抗体-药物偶联物。。

Diffuse Large B-cell Lymphoma Pipeline Therapies and Companies

弥漫性大B细胞淋巴瘤管道疗法和公司

Epcoritamab: AbbVie and Genmab

Epcoritamab:AbVie和Genmab

Zilovertamab vedotin: Merck

投票支持齐洛他单抗：默克

Glofitamab: Roche

Glophytamab：岩石

Plamotamab: Xencor and Janssen

普拉莫塔单抗：Xencor和Janssen

Enzastaurin (DB102): Denovo Biopharma

Enzastaurin（DB102）：Denovo生物制药

Mivavotinib: Calithera Biosciences

Mivavotinib：Calithera Biosciences

Maveropepimut-S: IMV

Maveropimut-S:IMV

LUNSUMIO (mosunetuzumab): Roche and Biogen

LUNSUM（mosunetuzumab）：罗氏和Biogen

Obe-cel: Autolus Therapeutics

Obe-cel：自体疗法

ALLO-501A: Allogene Therapeutics

ALLO-501A：异基因治疗

YTB323: Novartis

YTB323:↓诺华

Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine

Zamtocabtagene autoleucel（MB-CART2019.1）：Miltenyi Biomedicine

Odronextamab (REGN1979): Regeneron Pharmaceuticals

奥曲单抗（REGN1979）：Regeneron Pharmaceuticals

Debio 1562: Debiopharm

Debio 1562：Debiopharm

ADCETRIS (Brentuximab Vedotin): Seagen/Takeda

ADCETRIS（Brentuximab Vedotin）：希根/武田

Magrolimab: Gilead Sciences

Magrolimab：吉利德科学

IMFINZI (durvalumab): AstraZeneca

IMFINZI（durvalumab）：阿斯利康

CALQUENCE (acalabrutinb): AstraZeneca

CALQUENCE（acalabrutinb）：阿斯利康

For a comprehensive view of the DLBCL market, check out the DLBCL Market Assessment

有关DLBCL市场的全面了解，请查看DLBCL市场评估

Follicular Lymphoma Market

滤泡性淋巴瘤市场

Follicular lymphoma, a subtype of low-grade non-Hodgkin lymphoma, stands out as the most frequently encountered variety. It materializes when white blood cells clump together, resulting in the formation of lumps within the lymph nodes or organs. The process of an indolent lymphoma evolving into an aggressive non-Hodgkin's lymphoma is described as transformation.

滤泡性淋巴瘤是低度非霍奇金淋巴瘤的一种亚型，是最常见的变种。当白细胞聚集在一起时，它就会出现，导致淋巴结或器官内形成肿块。惰性淋巴瘤演变成侵袭性非霍奇金淋巴瘤的过程被描述为转化。

As per the assessment done by DelveInsight, the incident population of follicular lymphoma in the 7MM countries was estimated to be 36K cases in 2020..

根据DelveInsight的评估，2020年7MM国家滤泡性淋巴瘤事件发生率估计为36K例。。

Follicular lymphoma treatment options encompass CAR T cell therapies, chemotherapy, radiation therapy, immunotherapy, and stem cell transplants. Patients diagnosed with early-stage follicular lymphoma (Ann Arbor stages I or II) may receive radiation therapy as a standalone treatment or in combination with chemotherapy.

滤泡性淋巴瘤治疗选择包括CAR T细胞疗法，化学疗法，放射疗法，免疫疗法和干细胞移植。诊断为早期滤泡性淋巴瘤（Ann Arbor I期或II期）的患者可接受放射治疗作为独立治疗或与化疗联合。

Those with advanced-stage disease are typically initiated with chemoimmunotherapy, which involves chemotherapy alongside anti-CD20 antibodies. Commonly employed antibodies in this context include rituximab (Rituxan) and obinutuzumab (Gazyva), both of which specifically target follicular lymphoma cells.

患有晚期疾病的患者通常采用化学免疫疗法开始，化学免疫疗法涉及与抗CD20抗体一起的化学疗法。在这方面常用的抗体包括利妥昔单抗（Rituxan）和obinutuzumab（Gazyva），两者都特异性靶向滤泡性淋巴瘤细胞。

For elderly patients without organ dysfunction, rituximab alone may be a suitable treatment option..

对于没有器官功能障碍的老年患者，单用利妥昔单抗可能是一种合适的治疗选择。。

As per DelveInsight analysis, the follicular lymphoma market size in the seven major markets was USD 1.4 billion in 2020. The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.

根据DelveInsight分析，2020年七大市场的滤泡性淋巴瘤市场规模为14亿美元。由于全球医疗保健支出数量的增加，预计未来几年滤泡性淋巴瘤市场的动态将发生变化。

Key players, such as Genentech, NeoImmuneTech, AstraZeneca, Takeda, and others are involved in developing drugs for transformed follicular lymphoma..

主要参与者，如Genentech，NeoImmuneTech，AstraZeneca，Takeda等参与开发转化滤泡性淋巴瘤的药物。。

Follicular Lymphoma Pipeline Therapies and Companies

滤泡性淋巴瘤管道疗法和公司

DRL_RI (Proposed rituximab biosimilar) with MabThera: Dr. Reddy's Laboratories Limited/Parexel

DRL_RI（拟议的利妥昔单抗生物仿制药）与MabThera:Reddy博士的实验室有限公司/Parexel

Ibrutinib: Janssen Research & Development, LLC/Pharmacyclics LLC.

伊布替尼：杨森研发有限责任公司/Pharmacyclics有限责任公司。

Lenalidomide Plus Rituximab: Celgene

来那度胺加利妥昔单抗：Celgene

Epcoritamab: AbbVie/Genmab

Epcoritamab:AbVie/Genmab

Tisagenlecleucel: Novartis

Tisangelecleucel：诺华

Abexinostat: Xynomic Pharmaceuticals, Inc.

Abexinostat:Xynomic Pharmaceuticals，股份有限公司。

Parsaclisib: Incyte Corporation

Parsaclisib:Incyte Corporation

Nivolumab: Bristol-Myers Squibb

尼沃单抗：百时美施贵宝

EO2463: Enterome

EO2463：

Betalutin: Nordic Nanovector

Betalutin：北欧纳米载体

CTX112: CRISPR Therapeutics

CTX112:CRISPR疗法

IGM-2323: IGM Biosciences, Inc.

IGM-23:IGM生物科学公司。

BGB-16673: BeiGene

BGB-16673:[UNK]百济神州

Tazemetostat: Epizyme, Inc./Ipsen

Tazemetostat：Epizyme，股份有限公司/Ipsen

To gain a deeper understanding of the follicular lymphoma market, be sure to explore the Follicular Lymphoma Market Outlook

为了更深入地了解滤泡性淋巴瘤市场，一定要探索滤泡性淋巴瘤的市场前景

Chronic Lymphocytic Leukemia Market

慢性淋巴细胞白血病市场

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that primarily affects the lymphocytes, a type of white blood cell crucial for the immune system. CLL is characterized by the gradual accumulation of abnormal lymphocytes in the blood and bone marrow. It is considered a chronic form of leukemia because it progresses slowly, often with minimal or no symptoms in the early stages.

慢性淋巴细胞白血病（CLL）是一种主要影响淋巴细胞的血癌，淋巴细胞是一种对免疫系统至关重要的白细胞。CLL的特征是血液和骨髓中异常淋巴细胞的逐渐积累。它被认为是慢性白血病，因为它进展缓慢，通常在早期阶段症状很小或没有症状。

CLL is the most common form of leukemia in adults, particularly in Western countries. Its prevalence tends to increase with age, with the majority of cases diagnosed in individuals over 60..

CLL是成人中最常见的白血病形式，尤其是在西方国家。它的患病率往往随着年龄的增长而增加，大多数病例被诊断为60岁以上的人。。

The treatment of chronic lymphocytic leukemia typically involves a carefully tailored approach, as the course of the disease can vary from person to person. Treatment decisions are often based on the stage and progression of CLL, as well as the individual's overall health and preferences. Some patients with early-stage CLL may not require immediate treatment and are instead monitored closely through a strategy known as 'watchful waiting.' When treatment is necessary, options include chemotherapy, targeted therapies, immunotherapy, and, in some cases, stem cell transplantation. .

慢性淋巴细胞性白血病的治疗通常涉及精心定制的方法，因为疾病的过程因人而异。治疗决策通常基于CLL的阶段和进展，以及个体的整体健康和偏好。一些患有早期CLL的患者可能不需要立即治疗，而是通过称为“注意等待”的策略进行密切监测当需要治疗时，选择包括化疗，靶向治疗，免疫治疗，以及在某些情况下的干细胞移植。 .

As per DelveInsight analysis, the chronic lymphocytic leukemia market is anticipated to increase at a significant CAGR by 2032. In recent years, the CLL market has witnessed a shift towards more targeted therapies, including BTK inhibitors and B-cell receptor pathway inhibitors. These novel treatments offer improved efficacy and reduced side effects, transforming the landscape of CLL management.

根据DelveInsight分析，到2032年，慢性淋巴细胞白血病市场预计将以显着的CAGR增加。近年来，CLL市场已经转向更具针对性的治疗，包括BTK抑制剂和B细胞受体途径抑制剂。这些新颖的治疗方法提高了疗效，减少了副作用，改变了CLL管理的格局。

Moreover, the growing understanding of CLL's genetic and molecular characteristics has paved the way for personalized medicine, enabling healthcare providers to tailor treatments to individual patients. .

此外，人们对CLL的遗传和分子特征的日益了解为个性化医学铺平了道路，使医疗保健提供者能够为个别患者量身定制治疗方案。 .

Chronic Lymphocytic Leukemia Pipeline Therapies and Companies

慢性淋巴细胞白血病管道疗法和公司

Oncoquest-CLL vaccine: XEME Biopharma Inc.

Oncoquest CLL疫苗：XEME Biopharma Inc。

GA101: Pharmacyclics LLC.

GA101：Pharmacyclics LLC。

Ibrutinib: Pharmacyclics LLC.

伊布替尼：Pharmacyclics LLC。

Acalabrutinib in Combination With ACP-319: Acerta Pharma BV

Acalabrutinib与ACP-319联合用药：Acerta Pharma BV

Xembify: Grifols Therapeutics LLC

Xembify：Grifols Therapeutics LLC

EGFRt/19-28z/4-1BBL CAR T cells: Juno Therapeutics, Inc.

EGFRt/19-28z/4-1BBL CAR T细胞：Juno Therapeutics，Inc。

ABBV-319: AbbVie

ABBV-319:AbbVie

Acalabrutinib: AstraZeneca/Parexel

阿卡拉布替尼：阿斯利康/帕莱克斯

VIP152: Vincerx Pharma, Inc.

VIP152:Vincerx Pharma，股份有限公司。

LOXO-305: Loxo Oncology, Inc.

LOXO-305:LOXO肿瘤，股份有限公司。

Panzyga: Octapharma

Panzyga：Octapharma

ACP-196: Acerta Pharma BV

ACP-196:Acerta Pharma BV

Explore in-depth for a comprehensive understanding of the Chronic Lymphocytic Leukemia Clinical Trials

深入探讨以全面了解慢性淋巴细胞白血病临床试验

Mantle Cell Lymphoma Market

套细胞淋巴瘤市场

Mantle cell lymphoma (MCL) represents a rare and aggressive form of non-Hodgkin lymphoma (NHL), originating from B Lymphocytes located in the mantle zone. These atypical B cells tend to congregate in lymph nodes or organs, potentially forming tumors and disrupting the normal functioning of the lymphatic system or the afflicted organ.

套细胞淋巴瘤（MCL）代表一种罕见的侵袭性非霍奇金淋巴瘤（NHL），起源于位于套区的B淋巴细胞。这些非典型B细胞倾向于聚集在淋巴结或器官中，可能形成肿瘤并破坏淋巴系统或患病器官的正常功能。

According to DelveInsight's analysis, mantle cell lymphoma frequency is usually higher in males than in females. .

根据DelveInsight的分析，男性的套细胞淋巴瘤频率通常高于女性。 .

The treatment of mantle cell lymphoma relies on a variety of factors, such as the disease stage, the patient's age, and their overall health. MCL is typically diagnosed at an advanced stage, necessitating treatment for the majority of patients. Although MCL poses treatment challenges, significant advancements have been made in finding novel therapeutic options.

套细胞淋巴瘤的治疗依赖于多种因素，如疾病分期，患者年龄和整体健康状况。MCL通常被诊断为晚期，需要对大多数患者进行治疗。尽管MCL带来了治疗挑战，但在寻找新的治疗选择方面已取得重大进展。

The primary recommended strategies for managing this cancer include Active Surveillance, Chemotherapy, Targeted Therapy, and Transplantation..

治疗这种癌症的主要推荐策略包括主动监测，化疗，靶向治疗和移植。。

The dynamics of the mantle cell lymphoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2023–2032.

由于诊断方法的改进，对疾病的认识提高，全球医疗保健支出的增加以及预计在预测期间将推出新兴疗法，套细胞淋巴瘤市场的动态预计将在未来几年发生变化。2023-2032年。

Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma. .

全球公司正在努力开发套细胞淋巴瘤的新治疗方法。 .

Mantle Cell Lymphoma Pipeline Therapies and Companies

套细胞淋巴瘤管道疗法和公司

Acalabrutinib in combination with BR: Acerta Pharma BV/AstraZeneca

Acalabrutinib与BR联合用药：Acerta Pharma BV/阿斯利康

ACP-196 (acalabrutinib): Acerta Pharma BV

ACP-196（阿克拉布替尼）：Acerta Pharma BV

BGB-11417: BeiGene

BGB-11417:.；百济神州

PRGN-3007: Precigen, Inc

PRGN-3007:Precisgen，股份有限公司。

Tazemetostat Pill: Epizyme, Inc.

Tazemetostat Pill:Epizyme，股份有限公司。

TGR-1202: TG Therapeutics, Inc.

TGR-1202:[UNK]TGTherapeutics，股份有限公司。

IKS03: Iksuda Therapeutics Ltd.

IKS03 Iksuda Therapeutics有限公司

L-Bcl-2 antisense oligonucleotide: Bio-Path Holdings, Inc.

L-Bcl-2反义寡核苷酸：Bio Path Holdings，Inc。

Zanubrutinib: BeiGene

Zanubrutinib:BeiGene

MB-106: Mustang Bio

MB-106:Mustang Bio

TL-895: Telios Pharma, Inc.

TL-895:Telios Pharma，股份有限公司。

Zilovertamab vedotin: VelosBio Inc.

Zilovtamab的科学知识：VelosBio股份有限公司。

To access a complete analysis of the mantle cell lymphoma market, visit Mantle Cell Lymphoma Market Assessment

要获得套细胞淋巴瘤市场的完整分析，请访问套细胞淋巴瘤市场评估

Marginal Zone Lymphoma Market

边缘区淋巴瘤市场

Marginal Zone Lymphoma (MZL), a subset of non-Hodgkin lymphomas (NHL) with a typically slow-growing course, comprises about 5‒17% of all NHL cases. MZL is further categorized into three subtypes, with extranodal MZL being the most prevalent (50‒70%), followed by splenic MZL (20%) and nodal MZL (10%).

边缘区淋巴瘤（MZL）是非霍奇金淋巴瘤（NHL）的一个子集，具有典型的缓慢生长过程，占所有NHL病例的约5-17%。MZL进一步分为三种亚型，结外MZL最常见（50-70%），其次是脾脏MZL（20%）和淋巴结MZL（10%）。

As per the assessment done by DelveIsnight, the total incident population of non-Hodgkin lymphoma (NHL) in the 7MM was estimated to be ~181K in 2022. Out of these the total incident population of MZL in the 7MM in 2022 was observed to be ~23K..

根据DelveIsnight所做的评估，7MM的非霍奇金淋巴瘤（NHL）事件总数估计在2022年约为181K。其中，2022年7MM的MZL事件总数约为23K。。

The selection of treatment for patients with marginal zone lymphoma is contingent upon factors such as the disease type, stage, and location. According to lymphoma organizations, MZL can be categorized into three distinct subtypes: MALT/extranodal, nodal MZL, and splenic MZL. The overall MZL treatment market is classified into three segments based on the progression of therapies, namely first-line, second-line, and third-line therapies.

边缘区淋巴瘤患者的治疗选择取决于疾病类型，分期和位置等因素。根据淋巴瘤组织，MZL可分为三种不同的亚型：MALT/结外，淋巴结MZL和脾MZL。整体MZL治疗市场根据治疗进展分为三个部分，即一线，二线和三线治疗。

First-line treatment primarily involves supportive therapies, including rituximab monotherapy, R-CHOP/R-CVP regimens, rituximab combined with bendamustine, cytotoxic chemotherapy, antiviral therapy for hepatitis C infection, and the administration of antibiotics/PPIs..

一线治疗主要涉及支持疗法，包括利妥昔单抗单药治疗，R-CHOP/R-CVP方案，利妥昔单抗联合苯达莫司汀，细胞毒性化疗，丙型肝炎感染的抗病毒治疗以及抗生素/PPI的给药。。

As per DelveInsight analysis, the marginal zone lymphoma market is anticipated to increase at a significant CAGR by 2032. In recent years, an improved understanding of the complex pathobiology of MZLs has resulted in the development of novel treatment strategies. Private and government organizations have taken certain initiatives to raise awareness about the disease.

根据DelveInsight分析，到2032年，边缘区淋巴瘤市场预计将以显着的CAGR增长。近年来，对MZL复杂病理生物学的深入了解导致了新的治疗策略的发展。私营和政府组织已采取某些措施提高对该疾病的认识。

With the lifestyle change, the patient pool of MZL has been increased drastically. MZL has been associated with immune system dysregulation as a result of sustained immune stimulation from chronic infections or autoimmune disorders. Furthermore, the researchers are mainly focused on the specific treatment of MZL.

随着生活方式的改变，MZL的患者人数急剧增加。由于慢性感染或自身免疫性疾病的持续免疫刺激，MZL与免疫系统失调有关。此外，研究人员主要关注MZL的具体治疗。

So, because of the increase in the side effects and less efficacious drugs, the demand for specific therapy also increases..

因此，由于副作用的增加和药物疗效的降低，对特定治疗的需求也在增加。。

Marginal Zone Lymphoma Pipeline Therapies and Companies

边缘区淋巴瘤管道疗法和公司

Loncastuximab tesirine: ADC Therapeutics S.A.

Loncastuximab tesirine:ADC Therapeutics S.A。

Rituximab plus Venetoclax: AbbVie

利妥昔单抗加Venetoclax:AbVie

EO2463: Enterome

EO2463：

Axicabtagene ciloleucel: Gilead Sciences

Axiabtagene cilloucel：吉利德科学

Cirmtuzumab plus Ibrutinib: Oncternal Therapeutics, Inc/Pharmacyclics LLC.

Circtuzumab加Ibrutinib：Oncternal Therapeutics，Inc/Pharmacyclics LLC。

L-Bcl-2 antisense oligonucleotide: Bio-Path Holdings, Inc.

L-Bcl-2反义寡核苷酸：Bio Path Holdings，Inc。

BGB-16673: BeiGene

BGB-16673:[UNK]百济神州

To delve into the MZL market landscape in more detail, access the Marginal Zone Lymphoma Market Report

为了更详细地了解MZL市场格局，请访问边缘区淋巴瘤市场报告

Waldenstrom Macroglobulinemia Market

Waldenstrom巨球蛋白血症市场

Waldenstrom Macroglobulinemia is a relatively uncommon B-cell lymphoma characterized by its slow growth. It accounts for less than 2% of non-Hodgkin's Lymphoma cases and is sometimes referred to as lymphoplasmacytic lymphoma (LPL) due to the presence of a monoclonal IgM paraprotein. According to DelveInsight's analysis, the total Incident population of Waldenstrom macroglobulinemia in the 7MM was estimated to be more than 3K in 2020. .

Waldenstrom巨球蛋白血症是一种相对罕见的B细胞淋巴瘤，其特征在于其生长缓慢。它占非霍奇金淋巴瘤病例的不到2%，由于存在单克隆IgM副蛋白，有时也称为淋巴浆细胞性淋巴瘤（LPL）。根据DelveInsight的分析，2020年7MM的Waldenstrom巨球蛋白血症总发病人数估计超过3K。

Imbruvica (ibrutinib), developed by Janssen/AbbVie, marked a groundbreaking achievement as the first drug to receive approval for treating adults with Waldenstrom macroglobulinemia. Since its introduction, this innovative medication has been administered to over 200,000 patients worldwide across various approved indications.

由Janssen/AbbVie开发的Imbruvica（ibrutinib）作为第一个获得批准用于治疗成人瓦尔登斯特伦巨球蛋白血症的药物，取得了突破性的成就。自推出以来，这种创新药物已在全球超过200000名患者的各种批准适应症中使用。

This includes more than 5,300 Waldenstrom macroglobulinemia patients in the United States. Imbruvica belongs to the class of small molecule inhibitors targeting BTK, a pivotal protein in the development of this condition. In 2015, Imbruvica received the green light from both the FDA and the European Commission for use in adult Waldenstrom macroglobulinemia patients..

这包括美国5300多名Waldenstrom巨球蛋白血症患者。Imbruvica属于一类靶向BTK的小分子抑制剂，BTK是这种疾病发展的关键蛋白。2015年，Imbruvica收到了FDA和欧盟委员会的绿灯，用于成人Waldenstrom巨球蛋白血症患者。。

Takeda Pharmaceuticals' Velcade (bortezomib) received approval from Japan's PMDA in 2019 for the treatment of multiple myeloma, mantle cell lymphoma, primary macroglobulinemia, and lymphoplasmacytic lymphoma. This drug acts as a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells.

武田制药的Velcade（硼替佐米）于2019年获得日本PMDA的批准，用于治疗多发性骨髓瘤，套细胞淋巴瘤，原发性巨球蛋白血症和淋巴浆细胞性淋巴瘤。该药物可作为哺乳动物细胞中26S蛋白酶体胰凝乳蛋白酶样活性的可逆抑制剂。

Although it's available in Japan, Velcade is currently undergoing clinical trials in Europe and the United States for its potential use in Waldenström's macroglobulinemia.

虽然它在日本有售，但Velcade目前正在欧洲和美国进行临床试验，因为它可能用于Waldenström的巨球蛋白血症。

As per DelveInsight analysis, the Waldenstrom macroglobulinemia market size in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan was found to be more than USD 130 million in 2020. DelveInsight's analysts estimate that the Waldenstrom macroglobulinemia market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies during the forecast period (2019–2032). .

根据DelveInsight分析，2020年美国，EU5（德国，西班牙，意大利，法国和英国）和日本的Waldenstrom巨球蛋白血症市场规模超过1.3亿美元。DelveInsight的分析师估计，Waldenstrom巨球蛋白血症市场预计将呈现积极增长，主要原因是预测期间（2019-2032）发病率增加和预计推出新疗法。 .

Waldenstrom Macroglobulinemia Pipeline Therapies and Companies

Waldenstrom巨球蛋白血症管道疗法和公司

BGB-11417: BeiGene

BGB-11417:.；百济神州

Dasatinib: Bristol-Myers Squibb

达沙替尼：百时美施贵宝

Ibrutinib + Venetoclax: AbbVie/Pharmacyclics LLC.

伊布替尼+Venetoclax:AbVie/Pharmacyclics LLC。

APG2575: Ascentage Pharma Group Inc.

APG2575:Ascentage Pharma Group股份有限公司。

Acalabrutinib (ACP-196): Acerta Pharma BV

Acalabrutinib（ACP-196）：Acerta Pharma BV

LP-168: Newave Pharmaceutical Inc

LP-168:Newave Pharmaceutical Inc

Nemtabrutinib: Merck Sharp & Dohme LLC

Nemtabrutinib：默克公司

Zanubrutinib: BeiGene

Zanubrutinib:BeiGene

PSB202: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

PSB202：齐鲁普吉特声音生物治疗药（dba声音生物制剂）

NX-2127: Nurix Therapeutics, Inc.

NX-2127:Nurix Therapeutics，Inc。

For a deeper understanding of the Waldenstrom macroglobulinemia market landscape, explore the Waldenstrom Macroglobulinemia Market Outlook

为了更深入地了解Waldenstrom巨球蛋白血症市场格局，探索Waldenstrom巨球蛋白血症市场前景

Burkitt Lymphoma Market

伯基特淋巴瘤市场

Burkitt lymphoma constitutes a relatively small portion of all non-Hodgkin lymphoma cases, accounting for approximately 1-5%. It exhibits a higher incidence among individuals of Caucasian descent compared to those of African or Asian heritage. Additionally, Burkitt lymphoma is more commonly diagnosed in males than in females.

伯基特淋巴瘤占所有非霍奇金淋巴瘤病例的相对较小部分，约占1-5%。与非洲人或亚洲人相比，白种人后裔的发病率更高。此外，伯基特淋巴瘤在男性中比在女性中更常见。

The average age at diagnosis for Burkitt lymphoma is 6 years, and the sporadic form of the disease is primarily localized to North America and Europe, with a median age of diagnosis at 45. According to DelveInsight's analysis, males are more affected than females, in the case of Burkitt lymphoma..

伯基特淋巴瘤的平均诊断年龄为6岁，该病的散发形式主要局限于北美和欧洲，诊断中位年龄为45岁。根据DelveInsight的分析，在Burkitt淋巴瘤的情况下，男性比女性受影响更大。。

The primary aim of Burkitt lymphoma treatment is to achieve a cure and maintain long-term control over the lymphoma. This involves managing symptoms, preventing their spread to other body parts, and minimizing the risk of recurrence. The choice of treatment is determined by various factors, including the lymphoma's stage, symptomatology, impact on daily life, overall health, and LDH levels.

伯基特淋巴瘤治疗的主要目的是实现治愈并维持对淋巴瘤的长期控制。这涉及管理症状，防止其扩散到其他身体部位，并将复发风险降至最低。治疗的选择取决于各种因素，包括淋巴瘤的分期，症状，对日常生活的影响，整体健康状况和LDH水平。

In 2021, the FDA granted approval to the first and only targeted drug therapy that is currently being used for the treatment of Burkitt lymphoma. The approval was granted to rituximab in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, Burkitt lymphoma..

2021年，FDA批准了目前用于治疗伯基特淋巴瘤的第一种也是唯一一种靶向药物治疗。利妥昔单抗联合化疗被批准用于先前未经治疗的晚期伯基特淋巴瘤患儿。。

As per DelveInsight analysis, the Burkitt lymphoma market is anticipated to increase at a significant CAGR by 2032. The emerging drugs for Burkitt lymphoma shall impact the market size significantly,  considering the pipeline with a variety of therapeutic classes in the periphery. At present, there are a decent number of biologics and drugs under investigation for the treatment of Burkitt lymphoma. .

根据DelveInsight分析，预计到2032年伯基特淋巴瘤市场将以显着的CAGR增长。考虑到外围有各种治疗类别的管道，伯基特淋巴瘤的新兴药物将显着影响市场规模。目前，有相当数量的生物制剂和药物正在研究中用于治疗伯基特淋巴瘤。 .

Burkitt Lymphoma Pipeline Therapies and Companies

伯基特淋巴瘤管道疗法和公司

Nivolumab and Lenalidomide: Bristol-Myers Squibb

尼沃单抗和来那度胺：百时美施贵宝

Brexucabtagene Autoleucel: Gilead Sciences

Brexucabtagene Autoleucel：吉利德科学

XmAb13676: Xencor, Inc.

XmAb13676:Xencor，股份有限公司。

Explore in-depth for a comprehensive understanding of the Burkitt Lymphoma Clinical Trials

深入探讨以全面了解伯基特淋巴瘤临床试验

Trending Oncology Reports

趋势肿瘤学报告

Non-Small Cell Lung Cancer Market

非小细胞肺癌市场

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others..

非小细胞肺癌市场洞察力，流行病学和市场预测-2032年报告深入了解该疾病，历史和预测的流行病学，以及市场趋势，市场驱动因素，市场障碍和关键的NSCLC公司，包括EMD Serono，Merck，CellBiomedicine Group，Inc.，Celgene，CellSight Technologies，Inc。，BeyondSpring Pharmaceuticals Inc.，J Ints Bio，Forward Pharmaceuticals Co.，Ltd.，AstraZeneca，Bristol-Myers Squibb，Teligene US，Rain Oncology Inc，ReHeva Biosciences，Inc.，Amgen，Novartis，RedCloud Bio，Parexel，Vitrac Therapeutics，LLC，Mythic Therapeutics，Instil Bio，Mirati Therapeutics Inc.，Daiichi Sankyo，Inc.，AstraZeneca，Precision Biologics，Inc.，Promontory。，Palobiofarma SL，Regeneron Pharmaceuticals，Revolution Medicines，Inc.，Cullinan Oncology，LLC，Iovance Biotherapeutics，Inc.，Innate Pharma等。。

Glioma Market

胶质瘤市场

Glioma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioma companies, including Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, among others..

胶质瘤市场见解，流行病学和市场预测-2032年报告深入了解该疾病，历史和预测的流行病学，以及市场趋势，市场驱动因素，市场障碍和关键胶质瘤公司，包括拜耳，Chimerix，Aivita Biomedical，Denovo Biopharma，Northwest Therapeutics，VBL Therapeutics，Laminar Pharmaceuticals，MedImmune，DNAtrix，Immunomic Therapeutics，Imvax，MimiVax，CNS Pharmaceuticals，Epitopoietic Research Corporation（ERC），Istari Oncology，SonALAsense，Kintara Therapeutics，Bristol-Myers Squibb，Medicenna Therapeutics，BioMimetix，Eisai and Merck Sharp＆Dohme，Kazia Therapeutics，Oblato，Genenta Science，Enterome，Inovio Pharmaceuticals，Karyopharm Therapeutics，VBI Vaccines，第一天生物制药，Servier，Orbus Therapeutics，TVAX Biomedical，AnHeart Therapeutics，Beigene，SpringWorks Therapeutics，Forma Therapeutics，Hoffmann-La Roche，Incyte Corporation，Eli Lilly等。。

Multiple Myeloma Market

多发性骨髓瘤市场

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others..

多发性骨髓瘤市场见解，流行病学和市场预测-2032年报告深入了解该疾病，历史和预测的流行病学，以及市场趋势，市场驱动因素，市场障碍和关键的多发性骨髓瘤公司，包括强生（Janssen），辉瑞，AbbVie和罗氏（Genentech），Regeneron Pharmaceuticals，Bristol-Myers Squibb，Celgene，Roche（Genentech），Arcellx，Novartis，Regeneron Pharmaceuticals，BeiGene，CARsgen Therapeutics，Cartesian Therapeutics，C4 Therapeutics，Heidelberg Pharma，Bristol-Myers Squibb，RAPA Therapeutics，AbbVie（TeneoOne），Takeda等。。

Connect with our team to get key updates and major breakthroughs happening in the Oncology Therapeutics Market

与我们的团队联系，获取肿瘤治疗市场上发生的关键更新和重大突破

About DelveInsight

关于DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthca3re sectors, we offer customized research solutions and insights to clients across the globe.

DelveInsight是一家领先的以医疗保健为重点的市场研究和咨询公司，为客户提供高质量的市场情报和分析，以支持明智的商业决策。凭借经验丰富的行业专家团队和对生命科学和健康领域的深入了解，我们为全球客户提供定制的研究解决方案和见解。

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

通过我们基于订阅的平台PharmDelve，可以轻松访问所有医疗保健和制药市场研究报告。。

Contact UsShruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com

Contact UsShruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

徽标：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源DelveInsight商业研究，LLP